Johannes Schumacher appears in one of Dr. Liau’s publications as a co-author in a 2017 study on medulloblastoma subtypes, published in Nature (Northcott et al., 2017). This suggests Schumacher is likely a researcher or scientist in the field of neuro-oncology or related disciplines, possibly affiliated with an institution collaborating with UCLA or Liau’s research network. However, no specific details about Schumacher’s role, institution, or direct connection to Liau beyond this publication are provided.
Johannes Schumacher as the Chief Executive Officer of Immucura.
Damn!!!!!
Johannes Schumacher collaborated with Dr. Linda Liau at UCLA on groundbreaking clinical trials involving DCVax-L, an experimental immunotherapy for glioblastoma multiforme (GBM), one of the most aggressive forms of brain cancer.
Bullish
Market Data 
Markets 
AI
